AbbVie nears Allergan lockup with EU antitrust approval—and only one selloff required

AbbVie and Allergan have waited expectantly to seal the deal on their $63 billion merger as international watchdogs took a close look at the combo. Now, they're almost home free. The EU says it's prepared to give a green light to the deal, provided the companies sell off Allergan's IL-23 med brazikumab.